BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Memento EPFL//
BEGIN:VEVENT
SUMMARY:Organoids to model human diseases
DTSTART:20230220T140000
DTEND:20230220T150000
DTSTAMP:20260415T044817Z
UID:fb3ef13a13c895814f195d104d874625ac4f35dd08d787c64561e7bb
CATEGORIES:Conferences - Seminars
DESCRIPTION:Dr. Hans Clevers is the Head of Pharma Research and Early Deve
 lopment\, and a member of the Corporate Executive Committee of Roche. He i
 s a Dutch molecular geneticist\, cell biologist and stem cell researcher. 
 Previously\, he headed a research group at the Hubrecht Institute for Deve
 lopmental Biology and Stem Cell Research and at the Princess Máxima Cente
 r in the Netherlands\, where he remains as an advisor. He is also a Profes
 sor in Molecular Genetics at the University of Utrecht.\nLgr5 Stem Cell-ba
 sed organoids in human disease\n\nThe intestinal epithelium is the most 
 rapidly self-renewing tissue in adult mammals. We originally defined Lgr5 
 as a Wnt target gene\, transcribed in colon cancer cells. Two knock-in all
 eles revealed exclusive expression of Lgr5 in cycling\, columnar cells at 
 the crypt base. Using lineage tracing experiments in adult mice\, we found
  that these Lgr5+ve crypt base columnar cells (CBC) generated all epitheli
 al lineages throughout life\, implying that they represent the stem cell o
 f the small intestine and colon. Lgr5 was subsequently found to represent 
 an exquisitely specific\, yet 'generic' marker for active epithelial stem 
 cells\, including in hair follicles\, kidney\, liver\, mammary gland\, inn
 er ear tongue and stomach epithelium. Single sorted Lgr5+ve stem cells can
  initiate ever-expanding crypt-villus organoids\, or so called 'mini-guts
 ' in 3D culture. The technology is based on the observation that Lgr5 is t
 he receptor for a potent stem cell growth factor\, R-spondin. Similar 3D c
 ultures systems have been developed for the Lgr5+ve stem cells of human st
 omach\, liver\, pancreas\, prostate and kidney. Using CRISPR/Cas9 technolo
 gy\, genes can be efficiently modified in organoids of various origins.
  Organoid technology opens a range of avenues for the study of developme
 nt\, physiology and disease\, for drug development and for personalized me
 dicine. In the long run\, cultured mini-organs may replace transplant orga
 ns from donors and hold promise in gene therapy. \n 
LOCATION:SV 1717 https://plan.epfl.ch/?room==SV%201717
STATUS:CANCELLED
END:VEVENT
END:VCALENDAR